Also found in: Medical, Wikipedia.
Related to trastuzumab: tamoxifen


A humanized monoclonal antibody used intravenously to treat certain types of breast cancer and gastric cancer.

[tras-, origin unknown + tu(mor) + -zu- (shortening and alteration of humanized) + m(onoclonal) a(nti)b(ody).]
Mentioned in ?
References in periodicals archive ?
M2 PHARMA-February 21, 2018-PharmaMar Antibody Conjugate Increases PFS in HER2-expressing Breast, Ovarian, and Gastric Cancers Compared to Trastuzumab
M2 EQUITYBITES-February 14, 2018-EU approves Celltrion's trastuzumab biosimilar
There is a high unmet medical need in patients that have HER2-positive MBC and have progressed on trastuzumab and [ado-]trastuzumab emtansine.
The first cohort, HER2-positive MBC patients who are progressing on anti-HER2 therapies including TDM-1, will receive MCLA-128 in combination with trastuzumab and chemotherapy.
Our credibility has been further endorsed by the recent USFDA approval of our Biosimilar Trastuzumab, which is also the first in the US.
Trastuzumab is an antibody that blocks the HER2 receptor, and adjuvant trastuzumab has been shown to increase overall survival (OS) and disease-free survival (DFS) in HER2-positive patients, but is associated with a risk of adverse cardiac events.
Liu therefore tapped Taiwan's Bureau of National Health Insurance (BNHI) population-representative database of 1,629 newly diagnosed IABC patients between 2004 and 2006 who received at various time periods the cancer drugs capecitabine sequential to anthracycline-plus-taxane-based regimens (ATC) and trastuzumab sequential to anthracycline-plus-taxane-based regimens (ATT) as second-line treatment.
In the trial of trastuzumab in gastric adenocarcinoma (ToGA), all patients were dual tested (ie, samples underwent both immunohistochemistry [IHC] and fluorescence in situ hybridization [FISH]) and if either was positive, they were eligible for randomization.
FOLLOWING the success of trastuzumab, Roche brings the latest innovations in the treatment of HER2-positive breast cancer, namely pertuzumab and trastuzumab emtansine (T-DM1), which can provide new hope for women to continue to have options when the disease gets worse.
Trastuzumab alone or combined with first-line chemotherapy in phase III clinical trials has given better overall response (OR), time to progression (TP) and OS rates than chemotherapy alone in ErbB2+MBC patients (1316).
Significant advancements in breast cancer treatment occurred in two hallmark eras; hormonal therapy was introduced in the 1980s as a treatment for estrogen or progesterone positive breast cancer, and trastuzumab was introduced in the 1990s as a targeted therapy in the treatment of HER2- positive breast cancer.
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity.